MA48486B1 - Polymères liant les protons pour administration orale - Google Patents

Polymères liant les protons pour administration orale

Info

Publication number
MA48486B1
MA48486B1 MA48486A MA48486A MA48486B1 MA 48486 B1 MA48486 B1 MA 48486B1 MA 48486 A MA48486 A MA 48486A MA 48486 A MA48486 A MA 48486A MA 48486 B1 MA48486 B1 MA 48486B1
Authority
MA
Morocco
Prior art keywords
proton
oral administration
binding polymers
animal
human
Prior art date
Application number
MA48486A
Other languages
English (en)
Other versions
MA48486A (fr
Inventor
Gerrit Klaerner
Eric F Connor
Randi K Gbur
Matthew J Kade
Paul H Kierstead
Jerry M Buysse
Michael J Cope
Kalpesh N Biyani
Son H Nguyen
Scott M Tabakman
Original Assignee
Tricida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tricida Inc filed Critical Tricida Inc
Publication of MA48486A publication Critical patent/MA48486A/fr
Publication of MA48486B1 publication Critical patent/MA48486B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/02—Alkylation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F271/00—Macromolecular compounds obtained by polymerising monomers on to polymers of nitrogen-containing monomers as defined in group C08F26/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/20—Chemical modification of a polymer leading to a crosslinking, either explicitly or inherently
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/24—Homopolymers or copolymers of amides or imides
    • C08J2333/26—Homopolymers or copolymers of acrylamide or methacrylamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions pharmaceutiques et méthodes de traitement d'un animal, y compris un être humain, et méthodes de préparation de telles compositions. Les compositions pharmaceutiques contiennent des polymères d'amine réticulés et peuvent être utilisées, par exemple, pour traiter des maladies ou d'autres conditions métaboliques dans lesquelles l'élimination des protons et / ou des ions chlorure du tractus gastro-intestinal fournirait des avantages physiologiques tels que la normalisation des concentrations sériques de bicarbonate et du ph sanguin. Chez un animal, y compris un humain.
MA48486A 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale MA48486B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462090287P 2014-12-10 2014-12-10

Publications (2)

Publication Number Publication Date
MA48486A MA48486A (fr) 2020-01-15
MA48486B1 true MA48486B1 (fr) 2021-03-31

Family

ID=55080167

Family Applications (3)

Application Number Title Priority Date Filing Date
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale
MA48486A MA48486B1 (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA41150A MA41150B1 (fr) 2014-12-10 2015-12-10 Polymères de liaison aux protons pour administration orale
MA053106A MA53106A (fr) 2014-12-10 2015-12-10 Polymères liant les protons pour administration orale

Country Status (26)

Country Link
US (3) US11311571B2 (fr)
EP (3) EP3229816B1 (fr)
JP (4) JP6903576B2 (fr)
KR (2) KR20240008418A (fr)
CN (2) CN113855703A (fr)
AU (2) AU2015360413B2 (fr)
BR (2) BR112017011838B1 (fr)
CA (3) CA2969238C (fr)
CY (2) CY1122928T1 (fr)
DK (2) DK3593808T3 (fr)
ES (2) ES2787218T3 (fr)
HK (1) HK1243952A1 (fr)
HR (2) HRP20200689T1 (fr)
HU (2) HUE052736T2 (fr)
IL (3) IL252439B (fr)
LT (2) LT3593808T (fr)
MA (3) MA41150B1 (fr)
MD (2) MD3229816T2 (fr)
ME (1) ME03783B (fr)
MX (3) MX2017007497A (fr)
PL (2) PL3229816T3 (fr)
PT (2) PT3229816T (fr)
RS (2) RS61409B1 (fr)
RU (2) RU2713416C2 (fr)
SI (2) SI3593808T1 (fr)
WO (1) WO2016094685A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2728778C2 (ru) 2013-06-05 2020-07-31 Трисида, Инк. Протон-связывающие полимеры для перорального введения
RU2713416C2 (ru) 2014-12-10 2020-02-05 Трисида, Инк. Протон-связывающие полимеры для перорального введения
CA3023264A1 (fr) * 2016-05-06 2017-11-09 Tricida, Inc. Compositions et methode pour traiter des troubles acide-base
MX2019007904A (es) 2016-12-28 2019-09-09 Fujifilm Corp Emulsion de polimero que contiene atomo de nitrogeno o la sal del mismo, metodo de produccion para el mismo y metodo de produccion para las particulas.
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
AU2018360867A1 (en) 2017-11-03 2020-04-30 Tricida, Inc. Compositions for and method of treating acid-base disorders
CA3102765A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Methode de traitement de troubles de l'equilibre acido-basique
WO2019236124A1 (fr) * 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
EP4053179A1 (fr) 2021-03-01 2022-09-07 Tricida Inc. Compositions pharmaceutiques à base de polymères réticulés de poly(allylamine)

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01100164A (ja) * 1987-10-12 1989-04-18 Shionogi & Co Ltd スルファモイル−２−ベンゾフランカルボン酸誘導体
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5556619A (en) * 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
CA2202397C (fr) 1994-10-17 2002-07-16 Peter W. Stacpoole Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
JP3952223B2 (ja) * 1997-05-28 2007-08-01 日東紡績株式会社 アリルアミン重合体
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
WO1999040990A1 (fr) 1998-02-17 1999-08-19 University Of Maryland Polymeres a fixation d'anions et leur utilisation
US6485703B1 (en) 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
US6271264B1 (en) 1998-12-01 2001-08-07 Geltex Pharmaceuticals, Inc. Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
AU2001241077A1 (en) 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
AU2001241095A1 (en) 2000-03-13 2001-09-24 Hisamitsu Pharmaceutical Co. Inc. Preventives and/or remedies for hyperphosphatemia
JP2002028737A (ja) 2000-07-07 2002-01-29 Fujitsu Ltd プレス打ち抜き加工方法及びプレス打ち抜き加工装置
MXPA03009572A (es) * 2001-04-18 2004-02-12 Genzyme Corp Formas de polialilamina con bajo contenido en sal.
CA2444347A1 (fr) 2001-04-18 2002-10-31 Genzyme Corporation Methode pour traiter la goutte et pour fixer l'acide urique
TW200304813A (en) 2002-03-11 2003-10-16 Novartis Ag Salts of organic acid
WO2004069866A1 (fr) 2003-02-10 2004-08-19 Autogen Research Pty Ltd Molecules therapeutiques
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
CA2551528A1 (fr) 2003-12-31 2005-07-21 Genzyme Corporation Agents sequestrants des acides biliaires a base de polymeres d'amine aliphatique a revetement gastro-resistant
EP1723968A1 (fr) 2004-01-29 2006-11-22 Keio University Substance modifiant la fonction des erythrocytes
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7429394B2 (en) 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
EP1732516B1 (fr) 2004-03-30 2009-12-30 Relypsa, Inc. Compositions pour liaison ionique
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
NZ552706A (en) 2004-07-19 2011-01-28 Nutricia Nv Use of aspartate for regulating glucose levels in blood
DE102004035808A1 (de) 2004-07-21 2006-03-16 Kasch, Helmut, Dr. Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070293429A1 (en) 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
WO2007004236A2 (fr) 2005-07-04 2007-01-11 Ramu Krishnan Medicament ou composes pharmaceutiques ameliores et preparation associee
CA2619591C (fr) 2005-08-18 2020-03-24 Globoasia, Llc Composes organiques ferriques, utilisations desdits composes et procedesde fabrication associes
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
DE112006002617T5 (de) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite
WO2007038801A2 (fr) 2005-09-30 2007-04-05 Ilypsa, Inc. Compositions de liaison aux cations monovalents comprenant des particules coeur-ecorce avec des ecorces polyvinyliques reticulees et procedes pour les utiliser
BRPI0616604A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para remover e composiÇço para seletivamente remover Íon de potÁssio do trato gastrintestinal de um mamÍfero, mÉtodo para seletivamente remover Íon de potÁssio de um meio-ambiente, composiÇço farmacÊutica, partÍcula de nécleo-envoltàrio, e, usos de uma partÍcula de nécleo-envoltàrio e de uma composiÇço farmacÊutica
CN101355953B (zh) 2005-11-08 2014-07-09 味之素株式会社 麻醉苏醒促进剂
JP2009514966A (ja) 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
ITMI20052461A1 (it) 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
RU2008136081A (ru) 2006-02-14 2010-03-20 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические составы с алифатическими аминными полимерами и способы их производства
EP2016114A2 (fr) 2006-05-05 2009-01-21 Genzyme Corporation Polymères de condensation d'amines comme agents séquestrants de phosphates
US20100135950A1 (en) 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
BRPI0715053A2 (pt) 2006-07-18 2013-03-19 Genzyme Corp composiÇço farmacÊutica, mÉtodo para tratar doenÇas, e, polÍmero
EP2046284A1 (fr) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions pour administration intranasale d'insuline humaine et leurs utilisations
CA2749074A1 (fr) 2006-09-01 2008-05-29 Usv Limited Procede de preparation d'hydrochlorure de sevelamer et formulation de celui-ci
WO2008027551A2 (fr) 2006-09-01 2008-03-06 Genzyme Corporation Compositions de dendrimères
US7964182B2 (en) 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
US8425887B2 (en) 2006-09-29 2013-04-23 Genzyme Corporation Amide dendrimer compositions
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
WO2008103368A1 (fr) 2007-02-23 2008-08-28 Genzyme Corporation Compositions de polymère amine
US20080207766A1 (en) 2007-02-27 2008-08-28 Agi Therapeutics Research Ltd. Methods and compositions for treating at least one upper gastrointestinal symptom
US20100196305A1 (en) 2007-03-08 2010-08-05 Dhal Pradeep K Sulfone polymer compositions
TWI445540B (zh) 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
EP2152277A1 (fr) 2007-04-27 2010-02-17 Genzyme Corporation Compositions dendrimères amido-amine
US8273384B2 (en) 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
CN101687961B (zh) 2007-07-11 2011-10-05 东丽株式会社 交联聚烯丙胺或其酸加成盐及其医药用途
EP2016947A1 (fr) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Nouveau processus à une étape pour préparer des polymères poly(allylamine) réticulés
WO2009023544A2 (fr) 2007-08-10 2009-02-19 Ilypsa, Inc. Compositions pharmaceutiques à base de polymères échangeurs d'anions en dose
US20090125433A1 (en) * 2007-11-13 2009-05-14 Franck Rene Mikulecz Best pre-match routing (of foreign exchange orders)
US20090156647A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
PA8807201A1 (es) 2007-12-14 2009-07-23 Genzyme Corp Composiciones farmaceuticas
WO2009078958A1 (fr) 2007-12-14 2009-06-25 Genzyme Corporation Compositions pharmaceutiques enrobées
JP2009179724A (ja) * 2008-01-31 2009-08-13 Toray Ind Inc 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途
WO2009097127A1 (fr) 2008-01-31 2009-08-06 Genzyme Corporation Compositions pharmaceutiques
CA2732764C (fr) 2008-03-11 2023-04-04 Livionex Inc. Procedes et compositions pour traiter une inflammation et des pathologies en relation avec une inflammation
CA2720865A1 (fr) * 2008-04-08 2009-10-15 Usv Limited Procede pour la fabrication d'un sel de polymere d'amine
ES2380162T3 (es) 2008-04-11 2012-05-09 Gp Investimenti S.R.L. Dispositivo de uso manual para el tratamiento de tejido humano con ultrasonidos
US20110142952A1 (en) 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
DE102008030046A1 (de) 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20100008988A1 (en) 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010022381A1 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Traitement d'une hyperkaliémie par des polymères d'échange de cation réticulés ayant des propriétés physiques améliorées
WO2010022380A2 (fr) 2008-08-22 2010-02-25 Relypsa, Inc. Compositions de polyfluoroacrylate stabilisé par polyol linéaire
WO2010035118A1 (fr) 2008-09-25 2010-04-01 Vive Nano, Inc. Procédés de production de nanoparticules de polymère et formulations d'ingrédients actifs
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010059384A1 (fr) 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant
US20100166861A1 (en) 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
US20110081413A1 (en) 2009-01-22 2011-04-07 Ashok Omray Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
EP2490675B1 (fr) 2009-10-22 2019-01-23 Synthon B.V. Composition pharmaceutique comprenant sevelamer
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
EP2538947B1 (fr) 2010-02-24 2016-08-17 Relypsa, Inc. Polyimidazoles pour emploi en tant qu'agents séquestrants d'acide biliaire
EP2539380B1 (fr) 2010-02-24 2015-08-19 Relypsa, Inc. Polyvinylamine, polyallylamine et polyéthylèneimine réticulées pour l'utilisation comme séquestrants de l'acide biliaire
IT1406068B1 (it) 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR101238210B1 (ko) 2011-06-30 2013-03-04 엘지전자 주식회사 이동 단말기
US20130137772A1 (en) 2011-11-29 2013-05-30 Raymond J. Bergeron Hydroxypolyamine salts
PL3730136T3 (pl) 2012-06-21 2024-03-25 Keryx Biopharmaceuticals, Inc. Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek
JP6475624B2 (ja) 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
RU2728778C2 (ru) 2013-06-05 2020-07-31 Трисида, Инк. Протон-связывающие полимеры для перорального введения
EP3747432A1 (fr) 2013-11-04 2020-12-09 Keryx Biopharmaceuticals, Inc. Citrate ferrique pour réduire l'insuffisance cardiaque chez des patients souffrant d'une maladie rénale chronique
RU2713416C2 (ru) 2014-12-10 2020-02-05 Трисида, Инк. Протон-связывающие полимеры для перорального введения
CA3023264A1 (fr) 2016-05-06 2017-11-09 Tricida, Inc. Compositions et methode pour traiter des troubles acide-base
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
WO2019090177A1 (fr) 2017-11-03 2019-05-09 Tricida, Inc. Méthode de traitement de troubles de type acide-base
AU2018360867A1 (en) 2017-11-03 2020-04-30 Tricida, Inc. Compositions for and method of treating acid-base disorders
CA3102765A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Methode de traitement de troubles de l'equilibre acido-basique
WO2019236124A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement de troubles de l'équilibre acido-basique
WO2019236639A1 (fr) 2018-06-04 2019-12-12 Tricida, Inc. Méthode de traitement des troubles de l'équilibre acido-basique
US20200306209A1 (en) 2019-03-27 2020-10-01 Tricida, Inc. Method of treating acid-base disorders

Also Published As

Publication number Publication date
IL278034A (en) 2020-11-30
MD3593808T2 (ro) 2021-05-31
SI3229816T1 (sl) 2020-09-30
BR122021001914B1 (pt) 2024-02-27
DK3229816T3 (en) 2020-04-27
HRP20210204T1 (hr) 2021-03-19
CY1124073T1 (el) 2022-05-27
IL252439B (en) 2020-10-29
CY1122928T1 (el) 2021-10-29
EP3593808A1 (fr) 2020-01-15
JP2020158530A (ja) 2020-10-01
MD3229816T2 (ro) 2020-07-31
ES2857177T3 (es) 2021-09-28
HUE052736T2 (hu) 2021-05-28
US20180021370A1 (en) 2018-01-25
EP3593808B1 (fr) 2020-12-09
HRP20200689T1 (hr) 2020-07-24
PT3229816T (pt) 2020-05-11
JP6921276B2 (ja) 2021-08-18
MA48486A (fr) 2020-01-15
HK1243952A1 (zh) 2018-07-27
JP6903576B2 (ja) 2021-07-14
RU2713416C2 (ru) 2020-02-05
DK3593808T3 (da) 2021-02-01
JP2017538822A (ja) 2017-12-28
BR112017011838B1 (pt) 2023-04-25
MA41150B1 (fr) 2020-06-30
CN107428955A (zh) 2017-12-01
KR102625115B1 (ko) 2024-01-12
SI3593808T1 (sl) 2021-03-31
AU2015360413A1 (en) 2017-06-08
ME03783B (fr) 2021-04-20
RS60208B1 (sr) 2020-06-30
RS61409B1 (sr) 2021-03-31
JP2023085428A (ja) 2023-06-20
PL3229816T3 (pl) 2020-09-21
US20220339186A1 (en) 2022-10-27
AU2015360413B2 (en) 2021-07-08
JP2021176971A (ja) 2021-11-11
PT3593808T (pt) 2021-02-11
CA2969238C (fr) 2023-10-17
CA3164664A1 (fr) 2016-06-16
RU2017124157A3 (fr) 2019-07-17
ES2787218T3 (es) 2020-10-15
LT3593808T (lt) 2021-02-25
MA53106A (fr) 2021-09-15
RU2020102937A (ru) 2020-02-13
IL290729A (en) 2022-04-01
WO2016094685A1 (fr) 2016-06-16
AU2021245144A1 (en) 2021-11-04
EP3229816A1 (fr) 2017-10-18
CA2969238A1 (fr) 2016-06-16
US20230405043A1 (en) 2023-12-21
US11311571B2 (en) 2022-04-26
CN107428955B (zh) 2021-09-21
MX2019014711A (es) 2020-02-12
PL3593808T3 (pl) 2021-06-14
US11738041B2 (en) 2023-08-29
CA3205149A1 (fr) 2016-06-16
MX2021004558A (es) 2022-05-03
MA41150A (fr) 2017-10-18
MX2017007497A (es) 2017-10-04
EP3229816B1 (fr) 2020-02-05
HUE049057T2 (hu) 2020-08-28
KR20170095269A (ko) 2017-08-22
LT3229816T (lt) 2020-05-25
RU2017124157A (ru) 2019-01-10
BR112017011838A2 (pt) 2017-12-26
AU2021245144B2 (en) 2024-01-11
CN113855703A (zh) 2021-12-31
IL252439A0 (en) 2017-07-31
IL278034B (en) 2022-04-01
JP7258087B2 (ja) 2023-04-14
KR20240008418A (ko) 2024-01-18
JP7536343B2 (ja) 2024-08-20
EP3718551A1 (fr) 2020-10-07

Similar Documents

Publication Publication Date Title
MA48486B1 (fr) Polymères liant les protons pour administration orale
MY197091A (en) Compositions for treating acid-base disorders
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA34002B1 (fr) Thérapie antivirale
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
UA111587C2 (uk) Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками
MA38521A1 (fr) Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration
FR3023166B1 (fr) Utilisation d'une composition pharmaceutique renfermant une pectine a titre de principe actif, dans la prevention et/ou le traitement des lesions cutanees impliquant un caractere inflammatoire
TH167851B (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค
RU2013139184A (ru) Препарат траметин для лечения желудочно-кишечных болезней телят и способ его применения